



# American Society of Addiction Medicine

4601 NORTH PARK AVENUE • UPPER ARCADE SUITE 101 • CHEVY CHASE, MD 20815-4520  
*TREAT ADDICTION. SAVE LIVES.*

## OFFICERS

### Acting President

Stuart Gitlow, M.D., M.P.H., M.B.A., FAPA

### Secretary

Herbert L. Malinoff, M.D., FACP, FASAM

### Treasurer

Lori Karan, M.D., FACP, FASAM

### Immediate Past President

Louis E. Baxter, Sr., M.D., FASAM

## BOARD OF DIRECTORS

### Directors-at-Large

Paul H. Earley, M.D., FASAM

Mark Kraus, M.D., FASAM

Petros Levounis, M.D., M.A., FASAM

Judith A. Martin, M.D.

A. Kenison Roy, M.D., FASAM

John C. Tanner, D.O., FASAM

### Regional Directors

#### Region I

Marc Galanter, M.D., FASAM

#### Region II

David Pating, M.D.

#### Region III

John P. Femino, M.D., FASAM

#### Region IV

Mark P. Schwartz, M.D., FASAM

#### Region V

J. Ramsay Farah, M.D., M.P.H., FAAP, FACMP,  
FASAM

#### Region VI

Dora D. Dixie, M.D.

#### Region VII

John Epling, Jr., M.D., FASAM

#### Region VIII

William F. Haning, III, M.D., FASAM, DFAPA

#### Region IX

Raju Hajela, M.D., M.P.H., FASAM

#### Region X

Richard Graves Soper, M.D., J.D., M.S., FASAM

### Ex-Officio

Gavin Bart, M.D., FASAM

Kelly Clark, M.D., M.B.A., FASAM

Brian Hurley, M.D., M.B.A.

Ilse R. Levin, D.O.

Surita Rao, M.D.

Scott Teitelbaum, M.D.

Penelope P. Ziegler, M.D., FASAM

Penny S. Mills, M.B.A., EVP/CEO

## FOUNDING PRESIDENT

Ruth Fox, M.D.

1895-1989

September 13, 2012

Margaret A. Hamburg, MD  
Commissioner  
US Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

Thank you for considering the July 25, 2012 petition from researchers and health officials to regulate labeling of opioid analgesics. I, as Acting President of the American Society of Addiction Medicine (ASAM), was one of the many signatories. While ASAM stands by the recommendations offered in the petition, it has come to our attention that the intent of our recommendations may not be clear. We would like to take this opportunity to elaborate on the aforementioned proposals.

ASAM's physician members are keenly aware of the rise in opioid prescription misuse, addiction and overdose. For many of our opioid-addicted patients, the genesis of this disease can be traced to chronic pain therapy. While chronic opioid therapy is safe and highly effective at managing severe pain for many chronic, non-cancer pain patients, it can lead to adverse outcomes (i.e., addiction) for others. The recommendations put forward in the July 25 petition are intended to both help prevent unintended prescription opioid addiction and mitigate the negative patient and public health consequences of uninformed and/or over-prescribing of opioid analgesics.

The relabeling proposals are not intended, in any way, to limit a chronic pain patient's access to clinically appropriate opioid pain therapy or to impinge upon a pain specialist's ability to make individual decisions regarding the most effective therapy for their legitimate pain patient.

It is a priority of the American Society of Addiction Medicine to contribute to the work of the many public health and public safety stakeholders addressing the issue of prescription drug abuse. To that end, we have published our public policy statement,

cosponsored the FDA REMS education proposals of the CORE Collaborative, and supported the many NIH prescription addiction screening, treatment and physician education initiatives.

We hope that the relabeling recommendations add to the ongoing efforts of the Food and Drug Administration, the National Institutes of Health and the many public and private stakeholders to find the right balance between allowing access to life-saving pain therapies and limiting prescription drug misuse and diversion.

Sincerely,

A handwritten signature in black ink, appearing to read "Stuart Gitlow". The signature is fluid and cursive, with a large initial "S" and a long, sweeping underline.

Stuart Gitlow, MD, MBA, MPH, FAPA  
Acting President, American Society of Addiction Medicine